Spectrum Pharmaceuticals Inc (SPPI.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|81||2017||Chairman of the Board|
|59||2017||President, Chief Executive Officer, Director|
|49||2013||Chief Financial Officer, Executive Vice President|
|2017||Chief Operating Officer|
|76||2016||Lead Independent Director|
- BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis
- BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11
- BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2
- BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash
- BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility